New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareEloralintide vs Palmitoyl Tetrapeptide-7

Eloralintide vs Palmitoyl Tetrapeptide-7

Side-by-side comparison of key properties, dosing, and research.

GLP-1 / Weight Loss Agonists
Eloralintide
Skin & Cosmetic
Palmitoyl Tetrapeptide-7
Summary
Eloralintide is a long-acting amylin analog under development by OPKO Health. Amylin is co-secreted with insulin and regulates post-meal glucose by slowing gastric emptying, suppressing glucagon, and promoting satiety. Eloralintide is designed for once-weekly dosing, differentiating it from the short-acting pramlintide (Symlin). It is being studied for obesity and type 2 diabetes as a complement to GLP-1 based therapies.
Palmitoyl Tetrapeptide-7 (Rigin) is a cosmetic peptide consisting of palmitic acid linked to the tetrapeptide sequence GQPR (Gly-Gln-Pro-Arg). It was designed to mimic the biological activity of the IgG immunoglobulin C-terminus, which downregulates the production of interleukin-6 (IL-6), a key driver of skin aging and inflammation.
Half-Life
~7 days (estimated, long-acting design)
Topical penetration-dependent; effects last hours to days
Admin Route
SubQ
Topical
Research
Typical Dose
Under investigation in Phase 1/2 trials
2-5 ppm concentration in formulation
Frequency
Once weekly
Twice daily
Key Benefits
  • Once-weekly dosing (vs multiple daily injections for pramlintide)
  • Appetite suppression via central amylin receptor activation
  • Reduction in post-meal glucagon secretion
  • Complementary mechanism to GLP-1 agonists for combination therapy
  • Slows gastric emptying for prolonged satiety
  • Potential additive weight loss when combined with GLP-1 agents
  • Reduces IL-6 inflammatory cytokine in skin
  • Prevents 'inflammaging' of the skin
  • Inhibits MMP collagen-degrading enzymes
  • Synergistic with Matrixyl for anti-aging
  • Clinically tested for wrinkle and skin texture improvement
  • Well-tolerated topically
Side Effects
  • Nausea
  • Vomiting
  • Decreased appetite
  • Injection site reactions
  • +1 more
  • Contact sensitization (rare)
  • Well-tolerated at standard concentrations
Stacks With